The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 260-266

  Liu, Yan ^a   Litière, Saskia ^a   De Vries, Elisabeth Ge ^b   Sargent, Daniel ^d   Shankar, Lalitha ^e   Bogaerts, Jan ^a   Seymour, Lesley ^c  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c QUEEN S UNIVERSITY   (Canada)

^d MAYO CLINIC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Advanced MR techniques; FDG PET; RECIST; Targeted agents; Tumour assessment criteria

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BONE SCINTISCANNING; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; HEALTH SURVEY; HUMAN; MOLECULAR IMAGING; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; QUESTIONNAIRE; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; SOFT TISSUE TUMOR; TREATMENT RESPONSE;

EID: 84891825549     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.011     Document Type: Article

References (27)

1. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
2. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
3. S. Stroobants, J. Goeminne, and M. Seegers et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2003 2012 2020
4. R.S. Benjamin, H. Choi, and H.A. Macapinlac et al. We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764
5. W. Schima, and A. Kurtaran GIST: imaging diagnosis, staging, and response assessment Wien Med Wochenschr 159 2009 408 413
6. D. Wormanns, G. Kohl, and E. Klotz et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility Eur Radiol 14 2004 86 92
7. S. Keil, F.F. Behrendt, and S. Stanzel et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria Eur Radiol 18 2008 2456 2465
8. M. Fabel, H. von Tengg-Kobligk, and F.L. Giesel et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV - a feasibility study Eur Radiol 18 2008 1114 1122
9. B.B. Ertl-Wagner, J.D. Blume, and D. Peck et al. Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 Trial Eur Radiol 19 2009 599 609
10. M.J. Byrne, and A.K. Nowak Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 2004 257 260
11. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
12. E.L. van Persijn van Meerten, H. Gelderblom, and J.L. Bloem RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline Eur Radiol 20 2010 1456 1467
13. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
14. B.D. Cheson, B. Pfistner, and M.E. Juweid et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
15. B.D. Cheson, S.J. Horning, and B. Coiffier et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
16. H. Choi, C. Charnsangavej, and S.C. Faria et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753-9 2007 11
17. P.Y. Wen, D.R. Macdonald, and D.A. Reardon et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
18. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
19. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
20. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl. 1 2009 122S 150S
21. J.D. Wolchok, A. Hoos, and S. O'Day et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
22. H.H. Pien, A.J. Fischman, J.H. Thrall, and A.G. Sorensen Using imaging biomarkers to accelerate drug development and clinical trials Drug Discov Today 10 2005 259 266
23. R. Boellaard, M.J. O'Doherty, and W.A. Weber et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 2010 181 200
24. L.K. Shankar, J.M. Hoffman, and S. Bacharach et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
25. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
26. T. Hamaoka, J.E. Madewell, D.A. Podoloff, G.N. Hortobagyi, and N.T. Ueno Bone imaging in metastatic breast cancer J Clin Oncol 22 2004 2942 2953
27. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 52-60 2010 12